13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q1 2025 · Filed May 7, 2025 · Accession 0000950123-25-004223
Total Value
$60.2M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 5,652,922 | $26.2M | 43.56% |
| 2 | CRISPR Therapeutics AG | CRSP | 498,558 | $17.0M | 28.18% |
| 3 | Contineum Therapeutics, Inc. | CTNM | 918,163 | $6.4M | 10.64% |
| 4 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $3.2M | 5.30% |
| 5 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $2.6M | 4.33% |
| 6 | Tempest Therapeutics, Inc. | TPST | 3,507,055 | $2.6M | 4.30% |
| 7 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $2.2M | 3.68% |